AIMS: Trastuzumab is a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2) oncoprotein and is an effective therapy for HER2-overexpressing breast cancer. MYL-1401O is a trastuzumab biosimilar. Here, we report results from a phase 1 study that investigated bioequivalence among MYL-1401O, reference EU-trastuzumab and US-trastuzumab. METHODS: This single-centre, randomized, double-blind, three-arm, parallel-group, phase 1 study was conducted in healthy adult male volunteers. Subjects were randomized 1:1:1 to receive a single 8 mg kg-1 dose of MYL-1401O, EU-trastuzumab or US-trastuzumab as a 90-min intravenous infusion. The primary objective was to assess PK similarity among all three products. Primary endpoints assessed were peak serum concentration (Cmax), area under the serum concentration-time curve from time of dosing to time of last quantifiable concentration and from time of dosing to infinity. Secondary endpoints included time of Cmax, elimination rate constant, half-life, safety and immunogenicity. RESULTS: Of 132 subjects enrolled (44/treatment), 120 (MYL-1401O, n = 42; EU-trastuzumab, n = 41; US-trastuzumab, n = 37) were included in the PK analysis. The 90% confidence intervals of the ratios of geometric means for the primary endpoints were bounded within the predefined bioequivalence criterion of 80-125%. Secondary endpoints time of Cmax, elimination rate constant and half-life were similar among groups. All treatment-emergent adverse events were mild or moderate, similar across groups and no serious adverse events were reported. No treatment-related antidrug antibodies were detected. CONCLUSIONS:MYL-1401O was well tolerated and demonstrated PK and safety profiles similar to EU-trastuzumab and US-trastuzumab in healthy volunteers (ClinicalTrials.gov, NCT02594761).
RCT Entities:
AIMS: Trastuzumab is a humanized monoclonal antibody that binds the humanepidermal growth factor receptor 2 (HER2) oncoprotein and is an effective therapy for HER2-overexpressing breast cancer. MYL-1401O is a trastuzumab biosimilar. Here, we report results from a phase 1 study that investigated bioequivalence among MYL-1401O, reference EU-trastuzumab and US-trastuzumab. METHODS: This single-centre, randomized, double-blind, three-arm, parallel-group, phase 1 study was conducted in healthy adult male volunteers. Subjects were randomized 1:1:1 to receive a single 8 mg kg-1 dose of MYL-1401O, EU-trastuzumab or US-trastuzumab as a 90-min intravenous infusion. The primary objective was to assess PK similarity among all three products. Primary endpoints assessed were peak serum concentration (Cmax), area under the serum concentration-time curve from time of dosing to time of last quantifiable concentration and from time of dosing to infinity. Secondary endpoints included time of Cmax, elimination rate constant, half-life, safety and immunogenicity. RESULTS: Of 132 subjects enrolled (44/treatment), 120 (MYL-1401O, n = 42; EU-trastuzumab, n = 41; US-trastuzumab, n = 37) were included in the PK analysis. The 90% confidence intervals of the ratios of geometric means for the primary endpoints were bounded within the predefined bioequivalence criterion of 80-125%. Secondary endpoints time of Cmax, elimination rate constant and half-life were similar among groups. All treatment-emergent adverse events were mild or moderate, similar across groups and no serious adverse events were reported. No treatment-related antidrug antibodies were detected. CONCLUSIONS:MYL-1401O was well tolerated and demonstrated PK and safety profiles similar to EU-trastuzumab and US-trastuzumab in healthy volunteers (ClinicalTrials.gov, NCT02594761).
Authors: Liselijn A B Wisman; Eduard P M De Cock; Joannes A A Reijers; Ingrid M C Kamerling; Sandra H G Van Os; Marieke L de Kam; Jacobus Burggraaf; Gerrit Voortman Journal: Clin Drug Investig Date: 2014-12 Impact factor: 2.859
Authors: Hope S Rugo; Abhijit Barve; Cornelius F Waller; Miguel Hernandez-Bronchud; Jay Herson; Jinyu Yuan; Rajiv Sharma; Mark Baczkowski; Mudgal Kothekar; Subramanian Loganathan; Alexey Manikhas; Igor Bondarenko; Guzel Mukhametshina; Gia Nemsadze; Joseph D Parra; Maria Luisa T Abesamis-Tiambeng; Kakhaber Baramidze; Charuwan Akewanlop; Ihor Vynnychenko; Virote Sriuranpong; Gopichand Mamillapalli; Sirshendu Ray; Eduardo P Yanez Ruiz; Eduardo Pennella Journal: JAMA Date: 2017-01-03 Impact factor: 56.272
Authors: X Zhu; Y Ding; Y Yu; M Wang; W Zhou; J Wang; X Zhu; H Zhang; M Wang; K Chai; X Zhang; A Luk; W Jiang; S Liu; Q Zhang Journal: Cancer Chemother Pharmacol Date: 2020-11-09 Impact factor: 3.333
Authors: Justin Stebbing; Paul N Mainwaring; Giuseppe Curigliano; Mark Pegram; Mark Latymer; Angel H Bair; Hope S Rugo Journal: J Clin Oncol Date: 2020-02-14 Impact factor: 44.544
Authors: Jason D Lickliter; Rakesh Naranbhai Dadhania; Ravi Kumar Trivedi; S R Naveen Kumar; Pramod Kumar Reddy Journal: Indian J Med Res Date: 2021-03 Impact factor: 5.274
Authors: Hope S Rugo; Eduardo J Pennella; Unmesh Gopalakrishnan; Miguel Hernandez-Bronchud; Jay Herson; Hans Friedrich Koch; Subramanian Loganathan; Sarika Deodhar; Ashwani Marwah; Alexey Manikhas; Igor Bondarenko; Guzel Mukhametshina; Gia Nemsadze; Joseph D Parra; Maria Luisa T Abesamis-Tiambeng; Kakhaber Baramidze; Charuwan Akewanlop; Ihor Vynnychenko; Virote Sriuranpong; Gopichand Mamillapalli; Sirshendu Roy; Eduardo Patricio Yanez Ruiz; Abhijit Barve; Adolfo Fuentes-Alburo; Cornelius F Waller Journal: Breast Cancer Res Treat Date: 2021-06-14 Impact factor: 4.872